Photodynamic therapy and prostate cancer

被引：9
作者：
Colin, P. [1 ,2 ]
Estevez, J. -P. [1 ]
Betrouni, N. [1 ]
Ouzzane, A. [1 ,2 ]
Puech, P. [1 ,3 ,4 ]
Leroy, X. [5 ]
Biserte, J. [2 ]
Villers, A. [1 ,2 ]
Mordon, S. [1 ]
机构：
[1] Univ Nord France, INSERM, U703, CHRU Lille, F-59120 Loos, France
[2] CHRU Lille, Serv Urol, Hop Claude Huriez, F-59037 Lille, France
[3] CHRU Lille, Serv Radiol Urogenitale, Hop Claude Huriez, F-59037 Lille, France
[4] CHRU Lille, ORL, Hop Claude Huriez, F-59037 Lille, France
[5] CHRU Lille, Serv Anatomopathol, Ctr Biol Pathol, F-59037 Lille, France
来源：
PROGRES EN UROLOGIE | 2011年 / 21卷 / 02期
关键词：
Photodynamic therapy; Prostate; Cancer; LIGHT DELIVERY; FOCAL THERAPY; IN-VIVO; RADIOTHERAPY;
D O I：
10.1016/j.purol.2010.07.018
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Purpose. - Photodynamic therapy (PDT) is an innovative therapeutic modality in urologic oncology. Material and methods. - We reviewed the current literature on principles and modalities of PDT in prostatic oncology. Results. - Focal therapy of prostate cancer is an application field of PDT. Clinical phase II studies are ongoing to determine PDT efficacy and safety in this indication. PDT as salvage treatment after prostatic radiotherapy has been tested. Carcinologic results were promising but important side effects were reported. Individual dosimetric planification is necessary to avoid this toxicity. Conclusion. - PDT first clinical experience for prostate cancer has showed its technical feasibility. Several research ways are currently in study to improve carcinologic efficacy and to limit potential side effects. (C) 2010 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码：85 / 92
页数：8
相关论文
共 29 条
  • [1] The place of photodynamic therapy in gynecology
    Ascencio, M.
    Collinet, P.
    Cosson, M.
    Vinatier, D.
    Mordon, S.
    [J]. GYNECOLOGIE OBSTETRIQUE & FERTILITE, 2007, 35 (11): : 1155 - 1165
  • [2] Protoporphyrin IX fluorescence photobleaching is a useful tool to predict the response of rat ovarian cancer following hexaminolevulinate photodynamic therapy
    Ascencio, Manuel
    Collinet, Pierre
    Farine, M. O.
    Mordon, Serge
    [J]. LASERS IN SURGERY AND MEDICINE, 2008, 40 (05) : 332 - 341
  • [3] The changing face of low-risk prostate cancer: Trends in clinical presentation and primary management
    Cooperberg, MR
    Lubeck, DP
    Meni, MV
    Mehta, SS
    Carroll, PR
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) : 2141 - 2149
  • [4] Treatment planning and dose analysis for interstitial photodynamic therapy of prostate cancer
    Davidson, Sean R. H.
    Weersink, Robert A.
    Haider, Masoom A.
    Gertner, Mark R.
    Bogaards, Arjen
    Giewercer, David
    Scherz, Avigdor
    Sherar, Michael D.
    Elhilali, Mostafa
    Chin, Joseph L.
    Trachtenberg, John
    Wilson, Brian C.
    [J]. PHYSICS IN MEDICINE AND BIOLOGY, 2009, 54 (08) : 2293 - 2313
  • [5] Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine-bombesin conjugate
    Dubuc, Celena
    Langlois, Rejean
    Benard, Francois
    Cauchon, Nicole
    Klarskov, Klaus
    Tone, Paul
    van Lier, Johan E.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (07) : 2424 - 2427
  • [6] Eggener SE, 2007, J UROLOGY, V178, P2260, DOI 10.1016/j.juro.2007.08.072
  • [7] Ficheux H., 2009, ANNALES PHARMACEUTIQUES FRANCAISES, V67, P32, DOI 10.1016/j.pharma.2008.10.013
  • [8] FIGGE FHJ, 1948, ANAT REC, V101, P657
  • [9] Focal therapy for kidney and prostate cancer
    Gill, Inderbir S.
    [J]. CURRENT OPINION IN UROLOGY, 2009, 19 (02) : 125 - 126
  • [10] Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI
    Gross, S
    Gilead, A
    Scherz, A
    Neeman, M
    Salomon, Y
    [J]. NATURE MEDICINE, 2003, 9 (10) : 1327 - 1331
123